Global Myasthenia Gravis Disease Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2031

Myasthenia Gravis Disease Market Analysis

The myasthenia gravis disease market is witnessing significant growth, driven by increasing awareness of the condition, advancements in treatment options, and a rising patient population. Recent developments, such as the FDA approval of UCB S.A.'s ZILBRYSQ (zilucoplan) for treating generalized myasthenia gravis in adults who are anti-acetylcholine receptor antibody-positive, mark a pivotal advancement in therapeutic options. In addition, the market is seeing a surge in investigational therapies targeting various aspects of the disease, including monoclonal antibodies and immunosuppressants, which aim to improve patient outcomes and quality of life. Moreover, ongoing clinical trials and research initiatives are expected to yield new treatment modalities, enhancing the overall management of this debilitating condition and driving revenue growth in the myasthenia gravis disease market.

Myasthenia Gravis Disease Market Size

The global myasthenia gravis disease market size was valued at USD 776.39 million in 2023 and is projected to reach USD 1776.37 million by 2031, with a CAGR of 10.9% during the forecast period of 2024 to 2031. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Myasthenia Gravis Disease Market Trends

“Rising Focus on Monoclonal Antibody Therapies”

The global myasthenia gravis disease market is poised for significant growth, driven by increasing awareness and advancements in treatment options. A notable trend shaping the market is the rising focus on monoclonal antibody therapies, which offer targeted approaches for managing myasthenia gravis symptoms. For instance, the FDA approval of Eculizumab (Soliris), a monoclonal antibody that inhibits complement activation, has demonstrated efficacy in reducing symptoms for patients with generalized myasthenia gravis. Such innovative therapy represents a shift toward personalized medicine, addressing the specific immune mechanisms involved in the disease. As the healthcare sector invests more in research and development, the market for myasthenia gravis treatments is anticipated to grow, enhancing the quality of life for those affected by this chronic autoimmune disorder.

Report Scope and Myasthenia Gravis Disease Market Segmentation

Myasthenia Gravis Disease Market Definition

Myasthenia gravis is a chronic autoimmune neuromuscular disorder characterized by weakness and rapid fatigue of voluntary muscles. It occurs when the immune system produces antibodies that block or destroy the communication between nerves and muscles, specifically targeting the acetylcholine receptors at the neuromuscular junction, leading to impaired muscle contraction. Myasthenia gravis disease symptoms includes difficulty swallowing, drooping eyelids, and generalized muscle weakness. Myasthenia gravis can affect muscles involved in breathing, facial expression, and limb movement, and while there is no cure, treatments such as medications and therapies can help manage the symptoms.

Myasthenia Gravis Disease Market Dynamics

Drivers

• Increasing Incidence and Prevalence of Myasthenia

The increasing incidence and prevalence of myasthenia gravis globally is significantly driving the demand for effective treatment options. According to a study published in National Institute of Health, U.S. the incidence of the disease is 4.1 to 30 cases per million person-years, and the prevalence rate ranges from 150 to 200 cases per million and this number is expected to grow as more healthcare providers recognize its symptoms and seek to diagnose affected individuals. Such heightened awareness facilitates earlier diagnosis and treatment and underscores the pressing need for effective therapeutic options, ultimately contributing to market growth in the myasthenia gravis landscape.

• Growing Geriatric Population

The growing geriatric population worldwide is a significant driver of the myasthenia gravis market, as the incidence of autoimmune diseases, including myasthenia gravis, tends to increase with age. According to the World Health Organization (WHO), the number of people aged 60 years and older is projected to reach 2.1 billion by 2050, nearly doubling from 1 billion in 2020. Such demographic shift is associated with a higher prevalence of autoimmune disorders, as studies indicate that the incidence of myasthenia gravis peaks in individuals aged 60 to 80,  underscoring the need for effective treatment options tailored to this age group. As the population ages, healthcare providers and pharmaceutical companies must prioritize the development of treatments that address the unique needs of geriatric patients, thus driving growth in the myasthenia gravis market.

Opportunities

• Rising Research and Development (R&D) Activities

The rise in research and development (R&D) activities presents a significant opportunity for the myasthenia gravis disease market, as pharmaceutical companies and research institutions focus on discovering novel therapies to address this complex autoimmune disorder.  For instance, UCB S.A. has invested heavily in R&D for its drug Zilucoplan, which is in development for generalized myasthenia gravis. In addition, the National Institute of Neurological Disorders and Stroke (NINDS) is actively funding research into potential biomarkers for myasthenia gravis, which can aid in diagnosis and treatment efficacy. As R&D activities intensify, they are such asly to yield breakthrough therapies, thereby enhancing treatment options for patients and creating opportunities for the market in the upcoming years.

• Increasing Number of Clinical Trials

The increase in the number of clinical trials aimed at developing treatments for myasthenia gravis (MG) represents a substantial opportunity for the global myasthenia gravis disease market. As of 2023, over 30 active clinical trials are investigating various therapeutic approaches for MG, including new monoclonal antibodies, immunotherapies, and novel drug combinations. The growing recognition of the need for targeted therapies is reflected in investments by pharmaceutical companies. For instance, AstraZeneca and Amgen have recently increased their R&D budgets to accelerate clinical trials in autoimmune disorders, including MG. Such surge in clinical trials enhances the understanding of MG and paves the way for more effective management strategies, ultimately creating numerous opportunities in the market.

Restraints/Challenges

• High Treatment Costs

High treatment costs represent a significant challenge in managing myasthenia gravis, particularly as the market witnesses the emergence of novel therapies and long-term immunosuppressive treatments, which can be expensive. For instance, treatments such as eculizumab (Soliris), utilized for severe cases, can carry an extremely high annual cost per patient. Such a price tag can pose substantial barriers to access, particularly in developing countries where healthcare systems often operate under tight budget constraints and may not cover such expensive treatments. Consequently, many patients may resort to less effective or outdated therapies, resulting in poorer health outcomes, ultimately hindering the overall market growth.

• Emerging Alternative Treatments

Emerging alternative treatments pose a challenge to the myasthenia gravis market as there is increasing interest in non-pharmaceutical approaches, such as physical therapy and lifestyle modifications, which can complement or even replace traditional pharmacological treatments. For instance, physical therapy can enhance muscle strength and endurance, helping patients manage symptoms effectively without relying solely on medications. In addition, lifestyle changes, including a balanced diet and regular exercise, have been shown to improve overall well-being and may reduce the severity of symptoms for some individuals.  As more patients and healthcare providers recognize the benefits of these alternative methods, the demand for traditional treatments may be affected, potentially leading to restrictions in market growth.

This market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Myasthenia Gravis Disease Market Scope

The market is segmented on the basis of diagnosis, treatment type, route of administration, end users, and distribution channel. The growth amongst these segments will help you analyse meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Diagnosis

• Edrophonium Test
• Blood Test
• Repetitive Nerve Stimulation
• Single-fiber Electromyography (EMG)
• Others

Treatment Type

• Cholinesterase Inhibitors
• Corticosteroids
• Immunosuppressants
• Plasmapheresis
• Autologous Hematopoietic Stem Cell Transplantation (HSCT)
• Surgery
• Others

Route of Administration

• Oral
• Parenteral

End Users

• Hospitals
• Homecare
• Specialty Clinics
• Others

Distribution Channel

• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy

Myasthenia Gravis Disease Market Regional Analysis

The market is analysed and market size insights and trends are provided by country, diagnosis, treatment type, route of administration, end users, and distribution channel as referenced above.

The countries covered in the market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America holds a dominant position in the myasthenia gravis disease market, both in terms of market share and revenue, and is expected to maintain this lead throughout the forecast period. This dominance is driven by the rising incidence and prevalence of myasthenia gravis, particularly in the U.S., where increased awareness and advancements in treatment options have further fueled market growth. In addition, the region's well-established healthcare infrastructure and growing focus on autoimmune disorders contribute to the continued expansion of the market.

Asia-Pacific region is expected to experience the highest growth rate during the forecast period, driven by increasing research and development activities aimed at advancing treatments for myasthenia gravis. Countries such as China and India are investing heavily in healthcare innovation, fostering a robust environment for therapeutic advancements in autoimmune disorders. This regional focus on R&D is anticipated to significantly boost the availability and accessibility of novel treatment options for myasthenia gravis in the coming years.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.  

Myasthenia Gravis Disease Market Share

The market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to market.

Myasthenia Gravis Disease Market Leaders Operating in the Market Are:

• Alexion Pharmaceuticals, Inc. (U.S.)
• Bausch Health Companies Inc. (Canada)
• Novartis AG (Switzerland)
• Amneal Pharmaceuticals LLC (U.S.)
• Zydus Group (India)
• Avadel (Ireland)
• Dr. Reddy’s Laboratories Ltd (India)
• Fresenius Kabi AG (Germany)
• Endo Inc. (U.S.)
• Amphastar Pharmaceuticals, Inc. (U.S.)
• Viatris Inc. (U.S.)
• Aurobindo Pharma (India)
• Pfizer Inc. (U.S.)
• Astellas Pharma Inc. (Japan)
• F. Hoffmann-La Roche Ltd (Switzerland)
• Alkem (India)
• Hikma Pharmaceuticals PLC (U.K.)

Latest Developments in Myasthenia Gravis Disease Market

• In October 2023, UCB S.A., a global leader in biopharmaceuticals, announced that ZILBRYSQ (zilucoplan) received U.S. FDA approval for treating generalized myasthenia gravis (gMG) in adults who are anti-acetylcholine receptor (AChR) antibody-positive. This approval marks a significant advancement in the treatment of gMG, offering a targeted therapy for patients who previously had limited options
• In September 2023, Recipharm AB announced a strategic partnership with AHEAD THERAPEUTICS S.L. to advance the development of a new therapy for myasthenia gravis, a chronic autoimmune disorder. This collaboration focuses on scaling up the manufacturing capabilities for myasthenia gravis treatments, ensuring greater production capacity to meet growing patient needs

SKU-52388